CGRP & Migraine Research
Explore migraine research on CGRP biology, CGRP-targeted treatments, efficacy, safety and emerging therapeutics.
-
Plasma adrenomedullin and response to erenumab in migraine: a REFORM study.
Authors: Al-Khazali HM, Karlsson WK, Christensen RH, Dominguez-Moreno R, Ashina M Observational study
This research explored how plasma adrenomedullin levels relate to migraine treatment. Adrenomedullin is linked to migraine biology and resembles a key migraine-related peptide. Researchers wanted to know if measuring…
-
Efficacy and Safety of 2 Rimegepant Dosing Regimens for the Prevention of Episodic Migraine: A Randomized Controlled Study.
Authors: Goadsby PJ, Tassorelli C, Fountaine RJ, Antinew J, de Besi P Clinical trial
This study tested the effectiveness and safety of rimegepant for preventing migraines. Researchers focused on two dosing schedules compared to a placebo. Participants were adults with episodic migraines, experiencing…
-
Implementing Intravenous Eptinezumab in Routine Migraine Care: A Mixed-Methods Study of Patient and Healthcare Professional Perspectives.
Authors: Anukoolwittaya P, Hiransuthikul A, Sinchai K, Payuha T, Pongpitakmetha T Observational study
Eptinezumab is a new treatment for migraine prevention. It is given through an intravenous infusion every three months. This study focused on how patients and healthcare professionals feel about eptinezumab…
-
Real-world effectiveness and safety of eptinezumab in migraine prevention.
Authors: Pellesi L, Scuteri D, Allamprese R, Guerzoni S, Martelletti P Clinical trial
Eptinezumab is a new medication for preventing migraines. It is an intravenous treatment that targets a specific protein involved in migraine attacks. Previous studies showed it works well for both episodic and…
-
Sustained response to atogepant in episodic and chronic migraine: Post-hoc analyses of ELEVATE and PROGRESS, and their open-label extension.
Authors: Cho SJ, Friedman DI, Chalermpalanupap N, Nahas SJ, Dabruzzo B Clinical trial
These analyses looked at how effective atogepant is for migraine treatment. Atogepant is a daily pill that blocks certain pain signals. Researchers studied data from two trials called ELEVATE and PROGRESS. They also…
-
Atogepant for the preventive treatment of high-frequency episodic migraine: Subgroup analysis from the ADVANCE and ELEVATE trials.
Authors: Ashina H, Carr K, Lee MJ, Nagy K, Wang YF Clinical trial
Atogepant is a new oral medication for preventing high-frequency episodic migraines. High-frequency episodic migraine (HFEM) causes increased pain and difficulties in daily life. This research looked at how effective…
-
Persistence, effectiveness, and safety of CGRP-targeted therapies across therapeutic lines in resistant migraine: A real-world cohort study.
Authors: Pons-Fuster E, Muñoz-García I, Mancebo-González A, Espuny-Miró A, González-Ponce CM Observational study
Our research focused on how well patients with resistant migraines respond to CGRP-targeted therapies. We studied adults who received treatments like erenumab, fremanezumab, galcanezumab, atogepant, or rimegepant…
-
Differing roles of the calcitonin gene-related peptide (CGRP) and amylin receptors in migraine-related light aversion and gastrointestinal dysfunction in mice.
Authors: Waite JS, Kuburas A, Hanigan QK, Thoma JL, Rea BJ Laboratory / animal study
This research paper focuses on the role of two receptors in migraine symptoms. One receptor is calcitonin gene-related peptide (CGRP), which is important in migraine. The other is the amylin receptor (AMY1), which…
-
Treatment Optimization with Add-On Kampo Therapy in Highly Refractory Migraine Patients with Inadequate Response or Re-Worsening During CGRP Monoclonal Antibody Therapy: A Real-World Treatment Episode Analysis.
Authors: Tanei T, Yamashita S, Maesawa S, Ishizaki T, Suzuki T Observational study
This study looked at patients with migraines who didn't get enough relief from CGRP monoclonal antibody (CGRP-mAb) treatments. Researchers wanted to see if adding Kampo therapy could help. They included 39 patients…
-
Anxiety and Depression Symptoms During CGRP-Targeted Therapy in Patients with Migraine: A Retrospective Cohort Study from the United Arab Emirates.
Authors: Alsaadi T, Khandoker AH, Alkhateri A, Saidam M, Hamoulila K Observational study
Anxiety and depression are often seen in people with migraines. This study looked at whether CGRP-targeted therapies help reduce these symptoms. Researchers studied 121 adults in the UAE with migraines and anxiety or…
-
Contemporary diagnosis and management of vestibular migraine: a systematic review of conventional and CGRP-targeted therapies.
Authors: Alabood S, Aldokhail L, Alotaibi E, Alsaqr M, Alshehri A Systematic review / meta-analysis
Vestibular migraine (VM) causes recurring vertigo and significant disability for many patients. Traditional treatments vary in effectiveness, leaving some individuals without relief. New therapies targeting…
-
Critical comparison of ELISA kits for CGRP measurements in migraine.
Authors: de la Guerra-Sasián L, González-Quintanilla V, Madera J, Pérez-Pereda S, Pascual J Laboratory / animal study
We studied several commercial ELISA kits to measure CGRP levels in migraine. CGRP is a key biomarker linked to migraines, but its measurement reliability is debated. We tested serum samples from 19 migraine patients…
-
A Systematic Review of the Role of Monoclonal Antibodies as CGRP Inhibitors in Preventing Chronic and Episodic Migraine.
Authors: Hussen NH, Hamid SW, Hasan AH, Kamal MA Systematic review / meta-analysis
Migraine is a common and debilitating neurological condition affecting many people. Current treatments often do not provide sufficient relief or cause unwanted side effects. Researchers have focused on Calcitonin…
-
The role of neurogenic inflammation and CGRP in migraine headache.
Authors: Iannone LF, Calussi E, Bunnett NW, Geppetti P Review
Recent research has significantly changed how we understand migraines. It began with the discovery of calcitonin gene-related peptide (CGRP). This peptide is key in the process called neurogenic inflammation. This…
-
Development of a machine learning (ML) model to predict 3-month response to CGRP monoclonal antibodies in migraine: A pilot evaluation of physician-ML model interaction.
Authors: Katsuki M, Tatsumoto M, Shimazu T, Matsumori Y, Romozzi M Other / unclear
This study focused on predicting how well migraine patients respond to CGRP monoclonal antibodies (CGRP-mAbs). Researchers created a machine learning (ML) model to forecast treatment response after three months. They…
-
Effectiveness of rimegepant across multiple acute migraine attacks: A real-world, prospective, multicentric study.
Authors: Vaghi G, Ornello R, Sebastianelli G, Casillo F, Russo A Clinical trial
Rimegepant is a medication used to treat acute migraine attacks. This study looked at how well rimegepant works over multiple migraine events. Researchers followed 191 participants who experienced up to four…
-
Longitudinal effects of CGRP-targeting migraine therapies on blood pressure and body mass index: A 12-month retrospective analysis.
Authors: Phan P, Keith S, Li M, Hass R, Hsieh WJ Observational study
Researchers studied the effects of migraine therapies targeting CGRP on blood pressure and body mass index. CGRP is known to affect blood vessel function and metabolism. They compared patients using CGRP therapies…
-
Real-World Effectiveness and Tolerability of Rimegepant as Second- or Third-Line Acute Treatment for Migraine: A Prospective Observational Study.
Authors: Tanei T, Yamashita S, Yamamoto S, Muraoka S, Ishizaki T Observational study
Rimegepant is a medication for treating migraines. It works by blocking certain receptors in the brain. This study looked at how well rimegepant works when other treatments fail. Researchers followed 89 patients who…
-
Effectiveness of eptinezumab 300 mg dose escalation in partial responders to 100 mg among patients with difficult-to-treat migraine: A prospective, real-world study by the GRASP study group.
Authors: Dermitzakis EV, Argyriou AA, Rikos D, Chondrogianni M, Foska A Observational study
This study looked at how effective increasing the dose of eptinezumab is for patients with difficult-to-treat migraines. Researchers focused on adults who had high-frequency episodic or chronic migraines. These…
-
[Pharmacological properties and individualized selection of CGRP inhibitors for migraine prevention and acute treatment].
Authors: Batrakhanova MM, Dogadailova AM, Orekhova LE, Karlov NR, Anisimov II Review
This article reviews the use of CGRP inhibitors for migraine treatment. These include monoclonal antibodies and small-molecule receptor antagonists. Monoclonal antibodies like erenumab and fremanezumab have proven…
